Infant lymphoblastic leukemia: a single centers 10 year experience
Infant acute lymphoblastic leukemia (ALL) is a rare disease and consists of 4-5% of all childhood ALL. Despite improved survival rates in childhood ALL, infants with ALL have a worse prognosis. We aimed to evaluate the clinical features and treatment outcomes of our patients diagnosed with infant A...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hacettepe University Institute of Child Health
2019-06-01
|
| Series: | The Turkish Journal of Pediatrics |
| Subjects: | |
| Online Access: | https://turkjpediatr.org/article/view/698 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850236911805792256 |
|---|---|
| author | İnci Yaman-Bajin Selin Aytaç Barış Kuşkonmaz Duygu Uçkan-Çetinkaya Şule Ünal Fatma Gümrük Mualla Çetin |
| author_facet | İnci Yaman-Bajin Selin Aytaç Barış Kuşkonmaz Duygu Uçkan-Çetinkaya Şule Ünal Fatma Gümrük Mualla Çetin |
| author_sort | İnci Yaman-Bajin |
| collection | DOAJ |
| description |
Infant acute lymphoblastic leukemia (ALL) is a rare disease and consists of 4-5% of all childhood ALL. Despite improved survival rates in childhood ALL, infants with ALL have a worse prognosis. We aimed to evaluate the clinical features and treatment outcomes of our patients diagnosed with infant ALL at Hacettepe University, Pediatric Hematology Department between 1 January 2008 and 1 January 2018 retrospectively. There were 13 patients with a median age of 7 months. Three of the patients were triplets born from a spontaneous monozygotic triplet pregnancy. Relapse were observed in 4 patients. Hematopoietic stem cell transplantation (HSCT) was performed for five patients. Relapse after HSCT was observed in 3 patients. After a median follow-up period of 18 months, 6 patients (45%) (3 after HSCT and 3 who only received chemotherapy) were alive and in remission. Prognosis of infant ALL is poor in that only half of the patients survive. Our results suggest that bone marrow transplantation seems to be a good and efficient choice of treatment for selected patients. However, there is still a big issue to decide which patient should undergo transplantation and more studies are needed to reevaluate the eligibility criteria for HSCT in this group of patients.
|
| format | Article |
| id | doaj-art-1b32a1e2c9a7484e9d22fc52e07c181a |
| institution | OA Journals |
| issn | 0041-4301 2791-6421 |
| language | English |
| publishDate | 2019-06-01 |
| publisher | Hacettepe University Institute of Child Health |
| record_format | Article |
| series | The Turkish Journal of Pediatrics |
| spelling | doaj-art-1b32a1e2c9a7484e9d22fc52e07c181a2025-08-20T02:01:51ZengHacettepe University Institute of Child HealthThe Turkish Journal of Pediatrics0041-43012791-64212019-06-0161310.24953/turkjped.2019.03.002Infant lymphoblastic leukemia: a single centers 10 year experienceİnci Yaman-Bajin0Selin Aytaç1Barış Kuşkonmaz2Duygu Uçkan-Çetinkaya3Şule Ünal4Fatma Gümrük5Mualla Çetin6Division of Pediatric Hematology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.Division of Pediatric Hematology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.Division of Pediatric Hematology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.Division of Pediatric Hematology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.Division of Pediatric Hematology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.Division of Pediatric Hematology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.Division of Pediatric Hematology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey. Infant acute lymphoblastic leukemia (ALL) is a rare disease and consists of 4-5% of all childhood ALL. Despite improved survival rates in childhood ALL, infants with ALL have a worse prognosis. We aimed to evaluate the clinical features and treatment outcomes of our patients diagnosed with infant ALL at Hacettepe University, Pediatric Hematology Department between 1 January 2008 and 1 January 2018 retrospectively. There were 13 patients with a median age of 7 months. Three of the patients were triplets born from a spontaneous monozygotic triplet pregnancy. Relapse were observed in 4 patients. Hematopoietic stem cell transplantation (HSCT) was performed for five patients. Relapse after HSCT was observed in 3 patients. After a median follow-up period of 18 months, 6 patients (45%) (3 after HSCT and 3 who only received chemotherapy) were alive and in remission. Prognosis of infant ALL is poor in that only half of the patients survive. Our results suggest that bone marrow transplantation seems to be a good and efficient choice of treatment for selected patients. However, there is still a big issue to decide which patient should undergo transplantation and more studies are needed to reevaluate the eligibility criteria for HSCT in this group of patients. https://turkjpediatr.org/article/view/698acute lymphoblastic leukemiachemotherapyinfant leukemia |
| spellingShingle | İnci Yaman-Bajin Selin Aytaç Barış Kuşkonmaz Duygu Uçkan-Çetinkaya Şule Ünal Fatma Gümrük Mualla Çetin Infant lymphoblastic leukemia: a single centers 10 year experience The Turkish Journal of Pediatrics acute lymphoblastic leukemia chemotherapy infant leukemia |
| title | Infant lymphoblastic leukemia: a single centers 10 year experience |
| title_full | Infant lymphoblastic leukemia: a single centers 10 year experience |
| title_fullStr | Infant lymphoblastic leukemia: a single centers 10 year experience |
| title_full_unstemmed | Infant lymphoblastic leukemia: a single centers 10 year experience |
| title_short | Infant lymphoblastic leukemia: a single centers 10 year experience |
| title_sort | infant lymphoblastic leukemia a single centers 10 year experience |
| topic | acute lymphoblastic leukemia chemotherapy infant leukemia |
| url | https://turkjpediatr.org/article/view/698 |
| work_keys_str_mv | AT inciyamanbajin infantlymphoblasticleukemiaasinglecenters10yearexperience AT selinaytac infantlymphoblasticleukemiaasinglecenters10yearexperience AT barıskuskonmaz infantlymphoblasticleukemiaasinglecenters10yearexperience AT duyguuckancetinkaya infantlymphoblasticleukemiaasinglecenters10yearexperience AT suleunal infantlymphoblasticleukemiaasinglecenters10yearexperience AT fatmagumruk infantlymphoblasticleukemiaasinglecenters10yearexperience AT muallacetin infantlymphoblasticleukemiaasinglecenters10yearexperience |